Hyoscyamine
NDC Package 75929-057-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Hyoscyamine is sulfate extended-release tablets are effective as adjunctive therapy in the treatment of peptic ulcer. Marketed by Pharma Packaging Solutions, Llc Dba Tjopack Llc, this product is identified by NDC 75929-057.

Identification & Billing

NDC Package Code
75929-057-10
Package Description
100 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
75929-057
11-Digit Billing Format
75929005710

Clinical Specifications

Proprietary Name
Hyoscyamine ER
Dosage Form
-
Usage Information
Hyoscyamine sulfate extended-release tablets are effective as adjunctive therapy in the treatment of peptic ulcer. They can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder andmneurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Hyoscyamine sulfate extended-release tablets are indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a “drying agent” in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.

Regulatory & Marketing

Labeler Name
Pharma Packaging Solutions, Llc Dba Tjopack Llc
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
05-01-2016
End Marketing Date
07-24-2026
Listing Expiration
07-24-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 75929-057-10 identifies a specific commercial package of 100 tablet, extended release in 1 bottle of Hyoscyamine ER, labeled by Pharma Packaging Solutions, Llc Dba Tjopack Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Pharma Packaging Solutions, Llc Dba Tjopack Llc on May 01, 2016. The current certification is valid through July 24, 2026.

How is this Pharma Packaging Solutions, Llc Dba Tjopack Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 75929005710. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
75929-057-10
11-Digit CMS (5-4-2)
75929-0057-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.